HUGE FSD Pharma

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™.

Today, we’re following up on our August 2nd feature video in which we discussed UNBUZZD™, a proprietary formulation of natural ingredients, vitamins, and minerals to help relieve the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company, including a short video by Kevin Harrington of Shark Tank fame. If you are unable to view this video, please watch on InvestmentPitch Media’s YouTube channel at this link: ()

In that video, Kevin Harrington, an original “shark” on the TV hit show Shark Tank and the creator of the infomercial, introduced UNBUZZD™ and his involvement with the rapid detox drink.

Kevin has joined us again today to update us on the product and the impressive team he put together that has cumulatively generated billions of dollars of sales and value for brands and shareholders. Be sure to stay to the end of this short video, which Kevin sums up by giving the product his “whole-hearted endorsement”.

Following a product testing, John Duffy placed the following post on Facebook. “I had the pleasure of visiting our partners at the FSD Pharma (Nasdaq:HUGE) HQ in Toronto, Canada last week. On day one of my visit, I tried out samples of UNBUZZD and it is simply amazing!!! It was a tough workday, I had to get my Blood Alcohol Content (BAC) up to just under .08 (validated by a breathalyzer). I then tried UNBUZZD, within 30 minutes I started to become much more alert and focused. By the time I passed 70 minutes my BAC had dropped from just under .08 to just over .05. Later that day I participated in regular meetings and the dinner with board members and investors. I have worked in the food and beverage industry since I was in college. UNBUZZD is one of the most innovative and disruptive new products that I have seen during my career.”

According to Grandview Research, the global hangover cure products market size was estimated at US $2.3 billion in 2023 and is projected to grow at a compound annual growth rate of 14.8% from 2023 to 2030, reaching US $6.2 billion.

The company also recently reported that interim results for the first-in-human single ascending dose Phase I clinical trial for its novel drug candidate Lucid-21-302 (“Lucid-MS”), an orally-administered treatment for Multiple Sclerosis, showed the compound was well tolerated for the first 4 cohorts, with an addendum report describing the results of the fifth cohort due by the end of the month. In 2022, the Global MS treatment market was estimated at US$23 billion.

The shares are trading at US$1.40 on NASDAQ. For more information on the company’s drug candidates, please visit the company’s website, , or contact Zeeshan Saeed, Founder, President and Executive Co-Chairman, at 416-854-8884 or email or .

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

Disclaimer

The information in this Investmentpitch Media Ltd video is for the viewers information only. FSD Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by Investmentpitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. Investmentpitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.

CONTACT:

InvestmentPitch Media

Barry Morgan, CFO



EN
22/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FSD Pharma

 PRESS RELEASE

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Developme...

InvestmentPitch Media Video Discusses FSD Pharma’s Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington VANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, continues with the development of its exciting new rapid detox drink UNBUZZD™. Today, we’re following up on our August 2nd feature video...

 PRESS RELEASE

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Well...

TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today provides clarity and rebuttal to frivolous claims disparaging the Company and its groundbreaking efforts relating to its development of an innovative rapid alcohol detoxification drink, using its proprietary formulation developed to reduce the impacts of alcohol consumption. In May 2023, GBB Dri...

 PRESS RELEASE

InvestmentPitch Media Video Features FSD Pharma’s Definitive Agreement...

InvestmentPitch Media Video Features FSD Pharma’s Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is today’s feature company by InvestmentPitch Media. For more information, please view the InvestmentP...

 PRESS RELEASE

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Us...

TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201. In January 2022, Syneos Health (NASDAQ: SYNH) filed an arbitration proceeding against FSD Pharma claiming that the Company owed Syneos H...

 PRESS RELEASE

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Pre...

TORONTO--(BUSINESS WIRE)-- FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Company has retained Christian Attar Law, a regional litigation firm located in Houston, Texas, to co-lead, along with Alan M. Pollack of the New York City law firm Warshaw Burstein, LLP (collectively, the “Partners”), an investigation of any potential naked short selling or oth...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch